Neoadjuvant chemotherapy preceding cystectomy for bladder cancer

Area of Science:

• Oncology
• Urologic Oncology
• Cancer Chemotherapy

Background:

• Occult micrometastasis in muscle-invasive bladder cancer often leads to distant failure post-cystectomy.
• Locally advanced transitional cell carcinoma of the bladder presents significant treatment challenges.

Purpose of the Study:

• To review evidence supporting neoadjuvant chemotherapy for locally advanced bladder cancer.
• To highlight the role of neoadjuvant therapy in advancing systemic treatment development.

Main Methods:

• Review of randomized clinical trials and studies evaluating chemotherapy regimens.
• Analysis of data on survival benefits and prognostic factors associated with neoadjuvant chemotherapy.

Main Results:

• Adjuvant chemotherapy studies lacked sufficient statistical power.
• Cisplatin-based neoadjuvant combination chemotherapy demonstrated a survival benefit in randomized trials.
• Pathological complete remission is a strong predictor of long-term survival in neoadjuvant therapy trials.

Conclusions:

• Neoadjuvant chemotherapy is established as a standard treatment for locally advanced bladder cancer.
• The neoadjuvant chemotherapy paradigm facilitates the development of novel therapeutic agents.